Patritumab deruxtecan Antibody
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) designed for non-small cell lung cancer (NSCLC) research. It comprises a humanized anti-HER3 antibody conjugated via a cleavable linker to a topoisomerase I inhibitor payload (DXd) . This ADC is utilized in preclinical studies to investigate targeted cytotoxicity in both in vitro and in vivo HER3-expressing cancer models.
Product Specifications
Product Name Alternative
ADCs, AntibodyDrugConjugates, AntibodyDrugConjugates (ADCs), Antibody-Drug Conjugates, AntibodyDrug Conjugates (ADCs), HER3DXd, HER3-DXd, MK-1022, Patritumab deruxtecan, U31287, U3-1287
Target
Antibody-Drug Conjugates (ADCs)
Clonality
Monoclonal
Conjugation
Unconjugated
Concentration
10.45 mg/mL
Purity
>95.0% (May vary between batches)
Molecular Weight
155.2 kDa
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC942216-500 1x 500 µL
CD50 / ICAM3 (CG106), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940034-500 1x 500 µL
Cytokeratin 8/18 (C-51), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400177-100 1x 100 µL
CD50 (ICAM-3) (101-1D2), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740994-100 1x 100 µL
TNF alpha (J2D10), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details